From analyzing an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, an animal model of Parkinson disease, Doo et al. [45] suggested that BVA could effectively protect dopaminergic neurons against MPTP toxicity, possibly through the inhibition of Jun activation [45] and the phosphoinositide 3-kinases/protein kinase B (PKB) pathway (also known as Akt [PI3K/Akt]) [46]. Here, AKT1 is linked to Parkinson disease.